Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.33 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.33 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | GPR183 | P32249 | 1/20 | 0.33 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12883524 | 0.83 | LPL (0.43) | NPC1HPGDRAB9A | |
| SCHEMBL13555243 | 0.81 | APP (0.38) | NPC1HPGDRAB9ASLC6A2MMP12 | |
| SCHEMBL19088282 | 0.79 | TAAR1 (0.56) | SLC6A2 | |
| SCHEMBL16788858 | 0.79 | NPC1 (0.37) | NPC1HPGDRAB9ASLC6A2MMP12 | |
| SCHEMBL13635958 | 0.78 | ESR1 (0.52) | NPC1HPGDRAB9ASLC6A2 | |
| SCHEMBL31277355 | 0.78 | TAAR1 (0.52) | TNNC1SGPL1S1PR4S1PR1GPR183 | |
| SCHEMBL6248799 | 0.78 | HPGD (0.45) | NPC1HPGDRAB9AHDAC3HDAC4 | |
| SCHEMBL13884337 | 0.78 | LMNA (0.48) | HPGD | |
| SCHEMBL17917289 | 0.78 | NPC1 (0.38) | NPC1HPGDRAB9A | |
| SCHEMBL25881532 | 0.78 | ESR1 (0.52) | NPC1HPGDRAB9ASLC6A2TNNC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| US-20190144504-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-05-16 | — | — | US | disclosed |
| US-20180117163-A9 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2018-05-03 | — | — | US | disclosed |
| US-9938323-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2018-04-10 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | VARS1, GUSB, VAV1 | NPC1 798/4885HPGD 3418/4885RAB9A 257/4885 |
| US-20180117163-A9 | VAR2CSA-DRUG CONJUGATES | VARS1, GUSB, VAV1 | NPC1 798/4885HPGD 3418/4885RAB9A 257/4885 |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | NPC1 2704/4885HPGD 3861/4885RAB9A 1768/4885 |
| US-20190144504-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | NPC1 2791/4885HPGD 3966/4885RAB9A 1531/4885 |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | FCGRT, QARS1, INHA | NPC1 1960/4885HPGD 2797/4885RAB9A 740/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | NPC1 1960/4885HPGD 2797/4885RAB9A 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.